Beraprost

BLOOD AND BLOOD FORMING ORGANS

Key facts

Beraprost is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1992. DrugCentral lists 5 molecular targets, including PTGIR, Ptgir and Ptgir. Recorded indications include Pulmonary arterial hypertension.

• Molecular targets: PTGIR, Ptgir, Ptgir and PTGER3 (5 listed in DrugCentral).
• Indications: Pulmonary arterial hypertension.
• ATC code: B01AC19 (Platelet aggregation inhibitors excl. heparin).
• Molecular formula: C24H30O5; molecular weight 398.50 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Pulmonary arterial hypertension

Mechanism & targets

Molecular targets (5)

Target	Gene	Action	Activity
Prostacyclin receptor	PTGIR	agonist	IC50 8.37
Prostacyclin receptor	Ptgir	agonist	Ki 7.80
Prostacyclin receptor	Ptgir	agonist	Ki 7.72
Prostaglandin E2 receptor EP3 subtype	PTGER3	agonist	Ki 6.17
Prostaglandin E2 receptor EP4 subtype	PTGER4	agonist	Ki 5.14

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1992-01-01	YEAR INTRODUCED	—	—

ATC classification

ATC code	Therapeutic hierarchy
B01AC19	BLOOD AND BLOOD FORMING ORGANS › ANTITHROMBOTIC AGENTS › ANTITHROMBOTIC AGENTS › Platelet aggregation inhibitors excl. heparin

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Right ventricular failure	229.9
Cardiac failure	194.4
Pulmonary hypertension	188.3
Concomitant disease aggravated	182.9
Brain natriuretic peptide increased	141.0
Hepatic function abnormal	102.2
Pulmonary arterial hypertension	97.7
Anaemia	90.1
Upper respiratory tract inflammation	87.6
Transfusion	85.7
Platelet count decreased	79.9
Interstitial lung disease	66.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Beraprost is on its molecule page.

• Molecular formula: C₂₄H₃₀O₅
• Molecular weight: 398.50 g/mol
• CAS number: —
• InChIKey: CTPOHARTNNSRSR-APJZLKAGSA-N
• PubChem CID: 6917951

CC#CCC(C)[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2OC3=C(C=CC=C3CCCC(O)=O)[C@H]12

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Beraprost used for?

DrugCentral lists the following indications for Beraprost: Pulmonary arterial hypertension.

How does Beraprost work?

Its molecular targets in DrugCentral include PTGIR (agonist), Ptgir (agonist), Ptgir (agonist) and PTGER3 (agonist).

When was Beraprost first approved?

Beraprost was first approved by the YEAR INTRODUCED in 1992.

What is the chemical formula of Beraprost?

Beraprost has the molecular formula C24H30O5 and a molecular weight of 398.50 g/mol.

Sources

• DrugCentral drug card 343 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1207745 — compound record and bioactivity
• PubChem CID 6917951 — chemical identifiers
• DrugBank DB05229 — drug record
• FDA UNII 35E3NJJ4O6 — substance identity
• UniProt P43119 (PTGIR) — target protein
• UniProt P43115 (PTGER3) — target protein
• UniProt P35408 (PTGER4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.